FDA Issues Multiple Warning Letters Targeting Online Retailers and Pharmaceutical Manufacturers
The FDA has upped its game with increased enforcement action by releasing a number of warning letters to online retailers and drug manufacturers for their non-compliance with CGMPs and unauthorized drug promotion. This move shows that the FDA is putting more emphasis on patient safety, product quality, data integrity, and regulatory compliance in the international pharmaceutical supply chain.
Some of the pharmaceutical companies to receive FDA warning letters include the online retailing behemoth Amazon, South Korean pharmaceutical manufacturer Huons, and Canadian sterile drug manufacturer Jubilant HollisterStier. There were several issues with the violations involving unauthorized sales of drugs, data fabrication, and lack of proper control over sterile products.
Amazon Cited for Selling Unapproved Drug Products
One of the most significant enforcement actions taken is against Amazon, which was sent a warning letter by FDA investigators due to the presence of unapproved products available on the online website.
As per the agency, products such as Vajraang Phimosis Mini Combo, Penile Heal Cream, and Beilloso Balanitis Relief Cream are available for sale using the fulfillment by Amazon services. The aforementioned products are marketed to treat diseases such as phimosis and balanitis but are not FDA-approved.
These products are classified as new drugs according to the Federal Food, Drug, and Cosmetic Act and therefore require the approval of FDA before being sold in the United States.
In addition, the letter highlights that Amazon will have to take Corrective and Preventive Actions to identify the cause of the violations.
Wider Enforcement Against Online Health Product Sellers
Amazon was not the only entity under regulatory scrutiny; FDA also sent warning letters to various firms manufacturing goods that supposedly had the capability of treating different medical illnesses like cancer, impotence, prostate inflammation, among others without proper regulatory approval.
Some of the firms that were mentioned are:
• Herbal Dermals
• Wholesale Peptide
• Hadassah Healing Oils
• Texinkart
• Wild Arabic Herbs
• Indiangoods.shop
• Leading Edge Health
• Great India Overseas
• JJLBRO
• MantroForce
FDA still advises consumers to be wary of buying goods that claim to have medicinal capabilities without being properly approved by the FDA.
Huons Faces Serious Data Integrity and CGMP Violations
The South Korean company for drugs, Huons, received a warning letter following the FDA’s discovery of numerous CGMP and data integrity problems after inspecting the company.
One of the most worrying discoveries was related to the destruction and alteration of laboratory records. FDA investigators stated that almost 2,000 uncontrolled CGMP related documents were identified and there was proof of the falsification of testing data at the company’s laboratories.
The agency claims that the pages of logbooks were torn and substituted by fake documentation. The investigators revealed that testing results of bioburden samples were not provided and backdated, thus making a serious question about the accuracy of the quality control data.
While the company terminated the employment of those employees who participated in the fraud and established the special data integrity unit, FDA believes that there is no enough information provided on the measures that were taken.
Sterility Assurance and Equipment Control Deficiencies
Specifically, FDA pointed out the following:
• Insufficient investigation of unexpected discrepancies and failed batches
• Lack of sufficient aseptic processing controls
• Inadequate monitoring of sterile manufacturing environment
• Ineffective contamination control measures
• Failure to properly maintain equipment required for sterile manufacturing
FDA revealed inadequate measures for glove monitoring and decontamination in aseptic processing facilities. It was revealed that the procedures utilized by the company did not provide clear guidance on testing frequency, sampling needs, and sporicidal decontamination procedures essential for maintaining sterility.
This implies that there is a possibility of microbial contamination of sterile drug products manufactured by the company.
Jubilant HollisterStier Receives Warning Over Sterile Manufacturing Controls
The agency pointed to flaws in the design of aseptic processing procedures employed by the company and said that smoke studies to prove the flow pattern and the control of contamination were not adequate.
Furthermore, FDA pointed to improper investigation of excursions in environmental monitoring and events related to contamination. Several investigations conducted by the firm were either late or incomplete.
Quality System Failures Highlight Management Oversight Concerns
As per the statement made by the agency, the issues identified indicate that there was inadequate authority or poor execution of responsibilities by the quality unit. The FDA has also indicated that it is the responsibility of the management to conduct a thorough review of the manufacturing processes to meet regulatory requirements.
It is evident that senior management is responsible for having adequate quality systems in place.
Regulatory Implications for the Pharmaceutical Industry
Data Integrity is One of the Key Issues
It becomes very important for authorities to ensure that laboratory data, electronic records, and all documentation stay full, true, and attributable.
Controlling Standards for Sterile Production Become More Important
For manufacturers of injectable and sterile medications, there is a need for adequate control of contamination, validation of aseptic processing, and environmental monitoring.
Internet-Based Promotion of Health Products Is Monitored by Regulators
Due to the development of e-commerce, there is an increase in monitoring the promotion of products without approved therapeutic properties.
Management Control Is Required
FDA pays special attention to the fact that executives and quality management departments should have control over the compliance systems.
Conclusion
The warning letters sent out to Amazon, Huons, and Jubilant HollisterStier are indications of FDA’s dedication to protecting the public through strict enforcement of the drug approval process and compliance with CGMP. In either case of the sale of unapproved drugs online or in cases where there is a serious breach in the quality system of pharmaceutical manufacturers, FDA ensures that the industry receives a strong signal that effective compliance programs, good data integrity practices, and patient safety should be prioritized at all times.
As the expectation of regulation continues to change, pharmaceuticals and healthcare product retailers need to improve on their quality system, compliance and risk management.
Source: U.S. Food and Drug Administration (FDA) Warning Letters, June 2026.